This suggests that in malignant gliomas harboring BRAF V600E mutations, other pathways such as PI3K-Akt-mTOR pathway are also activated, BRAF V600E mutations are merely one of multiple driving mutations and may be present in a proportion of tumor cells, whereas in epithelioid GBMs, BRAF V600E mutation is likely a driving and recurrent event [7]. Here, BRAF is linked to malignant glioma.